Inside Forbes India

As life as we knew it came to a standstill in 2020, we capture both the spirit of innovation that prevailed in India during the pandemic, and acknowledge the various unsung heroes of Covid-19—from doctors to nurses, women of SHGs, municipal workers and ambulance drives, among so many others, who put their safety at stake to keep others safe

It took them a record 10 months to develop a H1N1 vaccine. Now Sharvil Patel, managing director, and his team at Zydus Cadila are trying to bring a Covid-19 vaccine by March 2021. Manu Balachandran and Divya Shekhar who have been closely following the vaccine race and India's play in it, take you behind the scenes of the ongoings at the Ahmedabad-based pharmaceutical

Forbes India's Manu Balachandran and Divya Shekhar take a jab at why this southern company, which may be a few laps behind the bigwigs in vaccine trials, could make up for lost time in its ability to scale. Will it play a big role in vaccinating India? Find out on this episode

Cover story author Divya Shekhar talks about how Covid-19 has helped rewrite the gospels of charity in India, engaging more than just billionaires

In a year that threw most projections out for a toss, some Indians managed to turn the tide. Many others didn't. Listen to Forbes India's Samar Srivastava detail the most interesting wins, losses and trends among India's billionaires from the Forbes India Rich List issue, which is now on stands

Ajay Singh, chairman & managing director, SpiceJet, has proved before that he can rewrite SpiceJet's trajectory. He's now looking to tap into existing revenue streams beyond passenger flights to keep the airline afloat—but the pandemic may not be the only headwind blowing its way

While the Russian Sputnik V vaccine follows a similar path as the Oxford-Astrazeneca vaccine of being based on the human adenovirus, a common cold virus fused with the spike protein of Sars-Cov-2 to stimulate an immune response, its approval and registration without the crucial Phase III trial and consequent tie-up with Dr Reddy's Laboratories has made headlines. Manu Balachandran, author of this fortnight's cover story delves into GV Prasad and Dr Reddy's long-standing relationship with Russia, the country's apparent transparency with the pharma company, and why it bet on the controversial vaccine

Build. Scale. Repeat: Ronnie Screwvala, who transformed UTV from a production company to a multimedia conglomerate, is now dipping into his entrepreneurial genius to build edtech startup upGrad into a venture of scale and impact. Can it compete with the likes of Byju's and Unacademy? Read more on www.forbesindia.com

By building new capabilities in digital, cloud, automation and AI, Infosys has won ever larger contracts. And the share of revenues from digital technology services as a proportion of the total has almost doubled in the last two years, to 45 percent.. Cover story author Harichandan Arakali speaks about the 'Salil Parekh flavour', the impact of H-1B visa restrictions on Infosys, and takes stock of the CEO and MD's biggest challenge yet: Ensuring the company stays on course Read the cover story here: https://www.forbesindia.com/article/ceo-work/cover-story-salil-parekhs-biggest-challenge-up-ahead/62551/1

In the April-June quarter, Britannia posted revenue of ₹3,384 crore, a spike of 26 percent over a year ago. Operating profit surged to ₹669 crore, a jump of 91 percent and profit after tax (PAT) zoomed by 118 percent to ₹546 crore. A lot happened behind the scenes to make it a cracking quarter, says Britannia MD Varun Berry. On this episode, cover story author Rajiv Singh delves into the details